A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
NCT ID: NCT06854952
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
167 participants
INTERVENTIONAL
2025-03-07
2025-09-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TERN-601 Dose 1
Orally administered once daily.
TERN-601
Investigational drug
TERN-601 Dose 2
Orally administered once daily.
TERN-601
Investigational drug
TERN-601 Dose 3
Orally administered once daily.
TERN-601
Investigational drug
TERN-601 Dose 4
Orally administered once daily.
TERN-601
Investigational drug
Matching Placebo
Orally administered once daily.
Matching Placebo
Matching placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TERN-601
Investigational drug
Matching Placebo
Matching placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index (BMI) of:
1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2
OR
2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
3. HbA1c \< 6.5%
4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)
Exclusion Criteria
2. Have obesity induced by medication or other diagnosed endocrinologic disorders
3. Have had or are planning surgical treatment or device-based therapy for obesity
4. Lifetime history of suicide attempt
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Terns, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FALCON Research Site
Birmingham, Alabama, United States
FALCON Research Site
Homewood, Alabama, United States
FALCON Research Site
Tucson, Arizona, United States
FALCON Research Site
Spring Valley, California, United States
FALCON Research Site
Port Orange, Florida, United States
FALCON Research Site
Louisville, Kentucky, United States
FALCON Research Site
Marrero, Louisiana, United States
FALCON Research Site
Boston, Massachusetts, United States
FALCON Research Site
Rochester, Minnesota, United States
FALCON Research Site
City of Saint Peters, Missouri, United States
FALCON Research Site
Beachwood, Ohio, United States
FALCON Research Site
Medford, Oregon, United States
FALCON Research Site
Dallas, Texas, United States
FALCON Research Site
Houston, Texas, United States
FALCON Research Site
San Antonio, Texas, United States
FALCON Research Site
St. George, Utah, United States
FALCON Research Site
Arlington, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TERN601-2003
Identifier Type: -
Identifier Source: org_study_id